{"id":8093,"date":"2025-07-12T07:11:24","date_gmt":"2025-07-12T10:11:24","guid":{"rendered":"https:\/\/vivadicas.com\/st2\/blog\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/"},"modified":"2025-07-12T07:11:26","modified_gmt":"2025-07-12T10:11:26","slug":"altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial","status":"publish","type":"post","link":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/","title":{"rendered":"#Altimmune’s $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial"},"content":{"rendered":"

Altimmune’s $alt has become the talk of Wall Street after the company reported impressive Phase 2b results for its flagship drug, pemvidutide, in the MASH trial. Investors are now closely watching $alt, as the news has driven a surge in trading volumes. With $alt gaining attention from both analysts and individual traders, the stock’s trajectory is being hotly debated.<\/p>\n

\ud83d\udcc8 Positive Data Propels $alt Higher<\/h3>\n

On June 26, 2025, Altimmune, Inc. (NASDAQ:ALT) revealed positive topline results from its closely watched Phase 2b clinical trial. The study focused on pemvidutide’s effects on metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with limited treatment options.<\/p>\n

The results showed statistically significant improvements in key endpoints, bringing hope to patients and investors alike. The announcement sent $alt shares climbing, with trading volumes far above average.<\/p>\n

\ud83c\udfaf Wall Street Reacts to Breakthrough<\/h3>\n

Goldman Sachs recently named Altimmune as one of its top penny stock picks. Following the trial results, analysts quickly weighed in, highlighting the potential for pemvidutide to disrupt the MASH treatment landscape. <\/p>\n

Industry experts believe that $alt could see continued momentum if Altimmune progresses to Phase 3 trials and regulatory approvals. Some are even comparing the opportunity to early-stage biotech success stories from the past decade.<\/p>\n

\ud83d\udca1 What This Means for Patients and Investors<\/h3>\n

MASH is a growing health concern, with millions affected in the US alone. The lack of approved therapies has left a significant unmet medical need. Altimmune’s pemvidutide, backed by the latest $alt trial results, could represent a breakthrough for patients.<\/p>\n

For investors, $alt has shifted from a speculative penny stock to a potential growth story with clinical merit. The company’s next steps, including further trials and regulatory discussions, will be closely watched by both the medical and financial communities.<\/p>\n

\ud83d\ude80 What’s Next for $alt and Altimmune?<\/h3>\n

Altimmune’s focus now turns to preparing for possible Phase 3 trials. The company will also engage with the FDA to discuss the regulatory pathway for pemvidutide. Positive feedback could accelerate $alt’s rise and bring the therapy to market sooner than expected.<\/p>\n

Market watchers suggest that any updates regarding collaborations, partnerships, or additional funding could further bolster $alt’s position. Altimmune’s progress in 2025 is set to be a major storyline for both biotech and investment circles.<\/p>\n

Altimmune’s $alt has captured headlines with its positive clinical data and promising future. Investors and patients alike will be eager for the next phase. Want to stay ahead of the news? Click to view and stay updated on $alt’s journey.<\/p>\n

Gostou de saber mais sobre $alt? Seus amigos tamb\u00e9m podem se interessar. Compartilhe<\/a> com eles agora mesmo!<\/p>\n","protected":false},"excerpt":{"rendered":"

Altimmune’s $alt has become the talk of Wall Street after the company reported impressive Phase 2b results for its flagship drug, pemvidutide, in the MASH trial. Investors are now closely watching $alt, as the news has driven a surge in trading volumes. With $alt gaining attention from both analysts and individual traders, the stock’s trajectory … Ler mais<\/a><\/p>\n","protected":false},"author":1,"featured_media":8092,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4017],"tags":[6639,6640,6643,6641,6642],"class_list":["post-8093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-eua","tag-alt","tag-altimmune","tag-biotech","tag-mash","tag-pharma"],"yoast_head":"\n#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com\" \/>\n<meta property=\"og:description\" content=\"Altimmune’s $alt has become the talk of Wall Street after the company reported impressive Phase 2b results for its flagship drug, pemvidutide, in the MASH trial. Investors are now closely watching $alt, as the news has driven a surge in trading volumes. With $alt gaining attention from both analysts and individual traders, the stock’s trajectory ... Ler mais\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\" \/>\n<meta property=\"og:site_name\" content=\"WordPulseTrends com\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-12T10:11:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-12T10:11:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"st2vivadicas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"st2vivadicas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\"},\"author\":{\"name\":\"st2vivadicas\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/f8432157bb5752f84d3a30f1c7388a16\"},\"headline\":\"#Altimmune’s $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial\",\"datePublished\":\"2025-07-12T10:11:24+00:00\",\"dateModified\":\"2025-07-12T10:11:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/#organization\"},\"image\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png\",\"keywords\":[\"$alt\",\"Altimmune\",\"biotech\",\"MASH\",\"pharma\"],\"articleSection\":[\"EUA\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\",\"url\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\",\"name\":\"#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com\",\"isPartOf\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png\",\"datePublished\":\"2025-07-12T10:11:24+00:00\",\"dateModified\":\"2025-07-12T10:11:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage\",\"url\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png\",\"contentUrl\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png\",\"width\":1024,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/vivadicas.com\/st2\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"#Altimmune’s $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#website\",\"url\":\"https:\/\/vivadicas.com\/st2\/\",\"name\":\"TrendsBrasil\",\"description\":\"Stay updated with trending topics, viral news, hot updates, breaking headlines, global trends, and real-time content. Discover what\u2019s going viral now and follow the most talked-about stories across the web, social media, and news platforms!\",\"publisher\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/vivadicas.com\/st2\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#organization\",\"name\":\"TrendsBrasil\",\"url\":\"https:\/\/vivadicas.com\/st2\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-24-de-jun.-de-2025-10_39_16-683x1024.png\",\"contentUrl\":\"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-24-de-jun.-de-2025-10_39_16-683x1024.png\",\"width\":683,\"height\":1024,\"caption\":\"TrendsBrasil\"},\"image\":{\"@id\":\"https:\/\/vivadicas.com\/st2\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/f8432157bb5752f84d3a30f1c7388a16\",\"name\":\"st2vivadicas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9bb04fcca59036779222f5f2d61adc27b9b487cc07bc4064b27fa7e0a1e23e1a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9bb04fcca59036779222f5f2d61adc27b9b487cc07bc4064b27fa7e0a1e23e1a?s=96&d=mm&r=g\",\"caption\":\"st2vivadicas\"},\"sameAs\":[\"https:\/\/vivadicas.com\/st2\"],\"url\":\"https:\/\/vivadicas.com\/st2\/author\/st2vivadicas\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/","og_locale":"pt_BR","og_type":"article","og_title":"#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com","og_description":"Altimmune’s $alt has become the talk of Wall Street after the company reported impressive Phase 2b results for its flagship drug, pemvidutide, in the MASH trial. Investors are now closely watching $alt, as the news has driven a surge in trading volumes. With $alt gaining attention from both analysts and individual traders, the stock’s trajectory ... Ler mais","og_url":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/","og_site_name":"WordPulseTrends com","article_published_time":"2025-07-12T10:11:24+00:00","article_modified_time":"2025-07-12T10:11:26+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png","type":"image\/png"}],"author":"st2vivadicas","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"st2vivadicas","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#article","isPartOf":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/"},"author":{"name":"st2vivadicas","@id":"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/f8432157bb5752f84d3a30f1c7388a16"},"headline":"#Altimmune’s $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial","datePublished":"2025-07-12T10:11:24+00:00","dateModified":"2025-07-12T10:11:26+00:00","mainEntityOfPage":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/vivadicas.com\/st2\/#organization"},"image":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage"},"thumbnailUrl":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png","keywords":["$alt","Altimmune","biotech","MASH","pharma"],"articleSection":["EUA"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/","url":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/","name":"#Altimmune's $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial - WordPulseTrends com","isPartOf":{"@id":"https:\/\/vivadicas.com\/st2\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage"},"image":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage"},"thumbnailUrl":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png","datePublished":"2025-07-12T10:11:24+00:00","dateModified":"2025-07-12T10:11:26+00:00","breadcrumb":{"@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#primaryimage","url":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png","contentUrl":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/07\/ai_trend_1752315066_ebd90a0d.png","width":1024,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/vivadicas.com\/st2\/eua\/altimmunes-alt-surges-after-positive-phase-2b-pemvidutide-results-in-mash-trial\/8093\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/vivadicas.com\/st2\/"},{"@type":"ListItem","position":2,"name":"#Altimmune’s $alt Surges After Positive Phase 2b Pemvidutide Results in MASH Trial"}]},{"@type":"WebSite","@id":"https:\/\/vivadicas.com\/st2\/#website","url":"https:\/\/vivadicas.com\/st2\/","name":"TrendsBrasil","description":"Stay updated with trending topics, viral news, hot updates, breaking headlines, global trends, and real-time content. Discover what\u2019s going viral now and follow the most talked-about stories across the web, social media, and news platforms!","publisher":{"@id":"https:\/\/vivadicas.com\/st2\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vivadicas.com\/st2\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/vivadicas.com\/st2\/#organization","name":"TrendsBrasil","url":"https:\/\/vivadicas.com\/st2\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/vivadicas.com\/st2\/#\/schema\/logo\/image\/","url":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-24-de-jun.-de-2025-10_39_16-683x1024.png","contentUrl":"https:\/\/vivadicas.com\/st2\/wp-content\/uploads\/2025\/06\/ChatGPT-Image-24-de-jun.-de-2025-10_39_16-683x1024.png","width":683,"height":1024,"caption":"TrendsBrasil"},"image":{"@id":"https:\/\/vivadicas.com\/st2\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/f8432157bb5752f84d3a30f1c7388a16","name":"st2vivadicas","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/vivadicas.com\/st2\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9bb04fcca59036779222f5f2d61adc27b9b487cc07bc4064b27fa7e0a1e23e1a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9bb04fcca59036779222f5f2d61adc27b9b487cc07bc4064b27fa7e0a1e23e1a?s=96&d=mm&r=g","caption":"st2vivadicas"},"sameAs":["https:\/\/vivadicas.com\/st2"],"url":"https:\/\/vivadicas.com\/st2\/author\/st2vivadicas\/"}]}},"_links":{"self":[{"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/posts\/8093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/comments?post=8093"}],"version-history":[{"count":1,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/posts\/8093\/revisions"}],"predecessor-version":[{"id":8094,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/posts\/8093\/revisions\/8094"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/media\/8092"}],"wp:attachment":[{"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/media?parent=8093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/categories?post=8093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vivadicas.com\/st2\/wp-json\/wp\/v2\/tags?post=8093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}